Mid-Year 2026 Workers’ Compensation Pharmacy Regulatory Recap: Three Developments to Watch
Setting the Stage
The first half of 2026 has reinforced a clear trend in workers’ compensation (WC) pharmacy: targeted regulatory action at the state level, especially around cost drivers and clinical oversight.
Here are three developments you should have on your radar heading into the second half of the year.
1. States Continue Updating Pharmacy Fee Schedules
Several states implemented or proposed updates to their workers’ compensation pharmacy fee schedules during the first half of 2026. These revisions address pharmacy reimbursement methodologies, physician‑dispensed medications, compounded products, and topical medications while providing greater clarity around payment policies. [1–3]
Arizona is one example. Effective May 1, 2026, the Industrial Commission of Arizona implemented updates to its Physicians’ and Pharmaceutical Fee Schedule. Among the revisions were updated reimbursement provisions for compounded topical medications, reimbursement limits for certain over‑the‑counter topical products, and continued use of Medi‑Span Average Wholesale Price (AWP) as the basis for pharmaceutical reimbursement calculations. [2]
Other jurisdictions also continued updating pharmacy reimbursement policies. Ohio proposed revisions to its workers’ compensation fee schedule, while Texas implemented annual reimbursement updates under its Medical Fee Guideline. [3,5]
Key Considerations
Pharmacy fee schedules establish the reimbursement framework for prescription medications within workers’ compensation systems. Periodic updates may affect reimbursement calculations, billing methodologies, physician‑dispensed medications, and pharmacy operations for payers, providers, pharmacies, and pharmacy benefit managers.
2. Continued Oversight of High-Cost Medications
States continue to evaluate medication categories associated with higher utilization or reimbursement costs, including compounded medications and topical analgesics.
In Texas, the Division of Workers’ Compensation (DWC) finalized its 2026 Medical Quality Review Annual Audit Plan, selecting topical analgesics as the focus of a plan‑based audit. The audit is intended to evaluate the medical necessity and appropriateness of topical analgesic prescribing within the Texas workers’ compensation system. [4]
This initiative reflects continued regulatory interest in understanding prescribing patterns and evaluating medication utilization within workers’ compensation programs.
Key Considerations
As states continue reviewing higher‑cost medication categories, stakeholders may see ongoing evaluation of prescribing practices, utilization review processes, and reimbursement policies related to these therapies.
3. Drug Formularies and Clinical Guidelines Continue to Evolve
Drug formularies and evidence‑based treatment guidelines remain central components of workers’ compensation pharmacy programs across many states.
California continued updating its Medical Treatment Utilization Schedule (MTUS) during 2026. Most recently, the Division of Workers’ Compensation adopted revisions to the MTUS Drug List, effective April 30, 2026, incorporating updated American College of Occupational and Environmental Medicine (ACOEM) clinical guidance. [6]
These formularies and treatment guidelines continue to support:
Evidence‑based prescribing
Utilization review decision‑making
Prior authorization processes
Consistency in pharmacy management
Key Considerations
As formularies and treatment guidelines continue to evolve, organizations involved in workers’ compensation pharmacy management may need to monitor updates that affect prescribing practices, utilization review processes, and documentation requirements.
Mid‑Year 2026: Key Regulatory Theme Takeaways
The first half of 2026 reflects continued state‑driven evolution in workers’ compensation pharmacy regulation, with three consistent themes:
Reimbursement modernization: States continue refining fee schedules and payment methodologies
Targeted oversight of higher‑cost medication categories: Regulators are focusing on compounded medications and topical analgesics
Strengthened clinical governance: Formularies and treatment guidelines continue to shape prescribing and utilization review
By Sarah Cirildo
PharmD
For questions, e-mail pharmd@prodigyrx.com
Citations
1. myMatrixx by Evernorth. Regulatory Rundown in Workers’ Comp Pharmacy: January 9, 2026. Published January 15, 2026. Accessed June 30, 2026. Regulatory rundown in workers' comp pharmacy January 9, 2026
2. Industrial Commission of Arizona. Arizona Physicians’ and Pharmaceutical Fee Schedule Frequently Asked Questions. Revised April 28, 2026. Accessed June 30, 2026. 2026 Fee Schedule FAQs_FINAL4.28.2026
3. Optum. Workers’ Comp 2026 Pharmacy Resource Guide. Published March 2026. Accessed June 30, 2026. Optum Workers' Comp 2026 Pharmacy Resource Guide
4. Texas Department of Insurance, Division of Workers’ Compensation. DWC Finalizes the 2026 Annual Audit Plan. Published April 23, 2026. Accessed June 30, 2026. DWC Finalizes the 2026 Annual Audit Plan
5. Texas Department of Insurance, Division of Workers’ Compensation. Medical Quality Review Calendar Year 2026 Annual Audit Plan. Published April 23, 2026. Accessed June 30, 2026. Medical Quality Review Calendar Year 2026 Annual Audit Plan.
6. California Department of Industrial Relations, Division of Workers’ Compensation. DWC Adopts Updates to MTUS Drug List Effective April 30, 2026. Published April 2026. Accessed June 30, 2026. DWC adopts updates to MTUS Drug List effective April 30, 2026 | California Department of Industrial Relations
